Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
Accession Number
DB00724  (APRD01030)
Small Molecule
Approved, Investigational

Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production. Miquimod is also used to treat a skin condition of the face and scalp called actinic keratoses and certain types of skin cancer called superficial basal cell carcinoma.

  • 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
  • 4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline
  • Imiquimod
  • Imiquimodum
External IDs
R 837 / R-837 / S 26308 / S26308
Product Ingredients
IngredientUNIICASInChI Key
Imiquimod acetateNot AvailableNot AvailableNot applicable
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AldaraCream50 mg/1gTopicalBausch Health US LLC1997-02-27Not applicableUs
AldaraCream50 mg/1000mgTopicalGraceway Pharmaceuticals2011-06-242015-01-31Us
AldaraCream50 mg/1000mgTopical3 M Pharmaceuticals2011-06-242015-01-31Us
AldaraCream50 mg/1000mgTopicalPhysicians Total Care, Inc.2003-06-192009-09-30Us
Aldara PCreamTopicalBausch Health, Canada Inc.1999-07-05Not applicableCanada
ImiquimodCream37.5 mg/1gTopicalOceanside Pharmacueticals2018-06-27Not applicableUs
ImiquimodCream50 mg/1000mgTopicalPerrigo New York Inc.2010-04-202013-08-01Us
Imiquimod 5%CreamTopicalValeant Canada Lp Valeant Canada S.E.C.Not applicableNot applicableCanada
VylomaCreamTopicalBausch Health, Canada Inc.2011-04-19Not applicableCanada
ZyclaraCream3.75 mg/100mgTopicalGraceway Pharmaceuticals2011-08-152015-01-31Us
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-imiquimodCreamTopicalApotex Corporation2013-12-31Not applicableCanada
ImiquimodCream50 mg/1gTopicalTeva2013-12-192015-04-30Us
ImiquimodCream50 mg/1000mgTopicalApotex Corporation2012-09-142018-04-24Us
ImiquimodCream50 mg/1gTopicalSandoz2011-02-282014-05-31Us
ImiquimodCream50 mg/1gTopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.2010-02-25Not applicableUs
ImiquimodCream50 mg/1gTopicalTaro Pharmaceutical Industries, Ltd.2011-04-15Not applicableUs
ImiquimodCream50 mg/1gTopicalGlenmark Pharmaceuticals Inc., USA2012-03-06Not applicableUs
ImiquimodCream50 mg/1gTopicalTaro Pharmaceuticals U.S.A., Inc.2011-04-15Not applicableUs
ImiquimodCream50 mg/1gTopicalPhysicians Total Care, Inc.2010-09-22Not applicableUs
ImiquimodCream12.5 mg/0.25gTopicalPerrigo New York Inc2010-11-09Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Imiquimod 5% / Levocetirizine Dihydrochloride 1% / Niacinamide 2%Imiquimod (5 g/100g) + Levocetirizine dihydrochloride (1 g/100g) + Nicotinamide (2 g/100g)GelTopicalSincerus Florida, LLC2019-05-01Not applicableUs
Imiquimod 5% / Levocetirizine Dihydrochloride 1% / Tretinoin 0.05%Imiquimod (5 g/100g) + Levocetirizine dihydrochloride (1 g/100g) + Tretinoin (0.05 g/100g)GelTopicalSincerus Florida, LLC2019-05-01Not applicableUs
Imiquimod 5% / Niacinamide 4%Imiquimod (5 g/100g) + Nicotinamide (4 g/100g)GelTopicalSincerus Florida, LLC2019-05-07Not applicableUs
Imiquimod 5% / Salicylic Acid 30% / Tretinoin 0.1%Imiquimod (5 g/100g) + Salicylic acid (30 g/100g) + Tretinoin (0.1 g/100g)GelTopicalSincerus Florida, LLC2019-05-07Not applicableUs
Imiquimod 5% / Tretinoin 0.025%Imiquimod (5 g/100g) + Tretinoin (0.025 g/100g)GelTopicalSincerus Florida, LLC2019-05-07Not applicableUs
International/Other Brands
Beselna (Mochida) / Imimore (Panalab) / Imiquad (Glenmark) / Labimiq (ITF - Labomed) / Li Di (Mingxin Pharmaceutical) / Miquimod (Lazar) / Nan Bo (Topfond Pharmaceutical) / Nilwart (Dr. Reddy's) / Omiquidar (Darier) / Tian Rui (Yangtze River Pharma) / Vetland (Landsteiner) / You Care (Nang Kuang) / Youbiqing (The United Laboratories Ltd)
CAS number
Average: 240.3036
Monoisotopic: 240.137496532
Chemical Formula
InChI Key



For the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Also indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above.

Associated Conditions

Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production. It is not used on warts inside the vagina, penis, or rectum. Imiquimod is also used to treat a skin condition of the face and scalp called actinic keratoses. Imiquimod can also be used to treat certain types of skin cancer called superficial basal cell carcinoma. Imiquimod is particularly useful on areas where surgery or other treatments may be difficult, complicated or otherwise undesirable, especially the face and lower legs.

Mechanism of action

Imiquimod's mechanism of action is via stimulation of innate and acquired immune responses, which ultimately leads to inflammatory cell infiltration within the field of drug application followed by apoptosis of diseased tissue. Imiquimod does not have direct antiviral activity. Studies of mice show that imiquimod may induce cytokines, including interferon-alpha (IFNA) as well as several IFNA genes (IFNA1, IFNA2, IFNA5, IFNA6, and IFNA8) as well as the IFNB gene. Imiquimod also induced the expression of interleukin (IL)-6, IL-8, and tumor necrosis factor alpha genes. In the treatment of basal cell carcinoma, Imiquimod appears to act as a toll-like receptor-7 agonist, and is thought to exert its anti-tumor effect via modification of the immune response and stimulation of apoptosis in BCC cells. In treating basal cell carcinoma it may increase the infiltration of lymphocytes, dendritic cells, and macrophages into the tumor lesion.

AToll-like receptor 7
UToll-like receptor 8
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more

Well absorbed through skin (as a cream)

Volume of distribution
Not Available
Protein binding
Not Available
Not Available
Route of elimination
Not Available
Half life

20 hours (topical dose), 2 hours (subcutaneous dose)

Not Available

Symptoms of overdose include flu-like symptoms, such as fever, fatigue, headache, nausea, diarrhoea and muscle pain.

Affected organisms
  • Humans and other mammals
Not Available
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
TacrolimusTacrolimus may increase the immunosuppressive activities of Imiquimod.
TrastuzumabTrastuzumab may increase the neutropenic activities of Imiquimod.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available


Synthesis Reference
General References
  1. van Egmond S, Hoedemaker C, Sinclair R: Successful treatment of perianal Bowen's disease with imiquimod. Int J Dermatol. 2007 Mar;46(3):318-9. [PubMed:17343595]
  2. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S: Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002 Feb;3(2):196-200. Epub 2002 Jan 22. [PubMed:11812998]
  3. Bilu D, Sauder DN: Imiquimod: modes of action. Br J Dermatol. 2003 Nov;149 Suppl 66:5-8. [PubMed:14616337]
  4. Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA: Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol. 1999 Jan;21(1):1-14. [PubMed:10411278]
External Links
Human Metabolome Database
PubChem Compound
PubChem Substance
Therapeutic Targets Database
RxList Drug Page Drug Page
ATC Codes
D06BB10 — Imiquimod
AHFS Codes
  • 84:92.00 — Misc. Skin and Mucous Membrane Agents
PDB Entries
5lbt / 5zsf
FDA label
Download (144 KB)
Download (36.3 KB)

Clinical Trials

Clinical Trials
0Active Not RecruitingTreatmentHigh Risk WHO Grade II Glioma / Recurrent/Post-Chemotherapy WHO Grade II Glioma1
0RecruitingPreventionCervical Intraepithelial Neoplasia Grade 2/3 / Cervical Squamous Cell Carcinoma In Situ / Cervical Squamous Intraepithelial Neoplasia 2 / High Grade Cervical Intraepithelial Neoplasia / P16 Positive Neoplastic Cells Present1
0RecruitingTreatmentLymphoma, T-Cell, Cutaneous1
0RecruitingTreatmentMetastatic Melanoma / Stage IIIB Cutaneous Melanoma AJCC v7 / Stage IIIC Cutaneous Melanoma AJCC v7 / Stage IV Cutaneous Melanoma AJCC v6 and v71
1Active Not RecruitingTreatmentColorectal Adenocarcinoma / Colorectal Cancers / Malignant Neoplasm of Pancreas / Pancreatic Ductal Adenocarcinoma / Stage IV Colorectal Cancer AJCC v7 / Stage IV Pancreatic Cancer AJCC v6 and v7 / Stage IVA Colorectal Cancer AJCC v7 / Stage IVB Colorectal Cancer AJCC v71
1Active Not RecruitingTreatmentSarcoma, Bone / Sarcomas / Soft Tissue Sarcoma (STS)1
1CompletedNot AvailableHealthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedPreventionInfluenza immunisation / Influenza, Avian1
1CompletedTreatmentActinic Keratosis (AK)2
1CompletedTreatmentAdenocarcinoma of the Prostate1
1CompletedTreatmentAnaplastic Astrocytoma (AA) / Ependymomas / Glioblastomas / Medulloblastomas / Neoplasms, Brain1
1CompletedTreatmentBreast Cancer / Malignant Neoplasm of Stomach1
1CompletedTreatmentCervical Intraepithelial Neoplasia (CIN 2/3) / HPV16 Positive / HPV16+1
1CompletedTreatmentCutaneous Neurofibromas / Neurofibromatosis Type 11
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentMalignant Gliomas1
1CompletedTreatmentMalignant Melanoma1
1CompletedTreatmentMelanoma (Skin)1
1CompletedTreatmentMelanoma (Skin) / Metastatic Cancers1
1CompletedTreatmentNon-Melanomatous Skin Cancer1
1Not Yet RecruitingTreatmentMelanoma (Skin)1
1Not Yet RecruitingTreatmentMetastatic Breast Cancer1
1RecruitingOtherHealthy Volunteers1
1RecruitingTreatmentBladder Cancers / Cholangiocarcinomas / Malignant Neoplasm of Colon / Malignant Neoplasm of Stomach / Ovarian Cancer / Palpable Subcutaneous Malignant Lesions / Tumors, Solid1
1RecruitingTreatmentBreast Cancer / Cervical Cancers / Esophageal Cancers / Hepatocellular,Carcinoma / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancer Small Cell Lung Cancer (SCLC) / Malignant Neoplasm of Stomach / Melanoma / Microsatellite Instability High / Neuroendocrine Carcinoma of the Skin / Ovarian Cancer / Squamous Cell Cancer / Transitional Cell Carcinoma1
1RecruitingTreatmentCervical Cancers / HPV Disease / Human Papilomavirus / Precancerous Conditions1
1RecruitingTreatmentSquamous Cell Carcinoma (SCC)1
1SuspendedTreatmentDiffuse Intrinsic Pontine Glioma (DIPG)1
1TerminatedTreatmentHPV 16- and/or HPV 18-Infected Women With Normal Cytology, ASCUS, or LSIL1
1, 2Active Not RecruitingTreatmentRecurrent Prostate Cancer1
1, 2CompletedTreatmentBreast Cancer / Metastatic Breast Cancer / Recurrent Breast Cancer1
1, 2CompletedTreatmentCarcinoma, Colorectal1
1, 2RecruitingTreatmentPrimary/Relapsed Acute Lymphoblastic Leukemia (ALL) of Childhood, Adolescents and Young Adults1
1, 2TerminatedTreatmentMalignancies / Progressive Solid Malignancies / Refractory Solid Malignancies1
1, 2TerminatedTreatmentMetastatic Melanoma1
2Active Not RecruitingTreatmentCervix Cancer / High Grade Intraepithelial Neoplasia / Uterine Cervical Neoplasm1
2Active Not RecruitingTreatmentFallopian Tube Cancer / Ovarian Cancer / Primary Peritoneal Cancer1
2Active Not RecruitingTreatmentHuman Papillomavirus (HPV) / Neoplasms, Vulvar / Pre-cancerous Lesions of the Vulva / VIN2 / VIN3 / Vulvar Dysplasia / Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) / Vulvar Intraepithelial Neoplasia (VIN)1
2CompletedNot AvailableActinic Keratosis (AK)1
2CompletedBasic ScienceVaginal Infections / Vaginal Inflammation1
2CompletedPreventionCervical Cancers / Precancerous Conditions1
2CompletedPreventionInfluenza Vaccines1
2CompletedTreatmentActinic Keratosis (AK)3
2CompletedTreatmentBreast Cancer / Neoplasms, Breast1
2CompletedTreatmentCarcinoma in Situ / Non Muscle Invasive Bladder Cancer1
2CompletedTreatmentExternal Genital Warts1
2CompletedTreatmentHemangioma, Capillary1
2CompletedTreatmentHigh-Risk Melanoma1
2CompletedTreatmentLeishmaniasis, Cutaneous1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2CompletedTreatmentMale Breast Cancer / Metastases to skin / Recurrent Breast Cancer / Stage IV Breast Cancer1
2CompletedTreatmentMalignant Melanoma1
2Enrolling by InvitationPreventionKeloid Scars1
2RecruitingTreatmentBasal Cell Carcinoma (BCC) / Basal Cell Carcinoma of Skin, Site Unspecified / Invasive Carcinoma / Skin Cancers1
2RecruitingTreatmentCervical Dysplasia / Cervical Intraepithelial Neoplasia (CIN)1
2RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)1
2TerminatedPreventionChronic Lymphocytic Leukaemia (CLL)1
2TerminatedTreatmentPort Wine Stains1
2, 3Active Not RecruitingPreventionHutchinson's Melanotic Freckle1
2, 3Active Not RecruitingTreatmentCervical Intraepithelial Neoplasia (CIN)1
2, 3CompletedPreventionRenal Failure1
2, 3CompletedPreventionViral Hepatitis B1
2, 3CompletedTreatmentCervical Intraepithelial Neoplasia (CIN)1
2, 3RecruitingTreatmentInflammatory Bowel Diseases (IBD) / Viral Hepatitis B1
2, 3Unknown StatusTreatmentBowens Disease1
3Active Not RecruitingTreatmentAnal Intraepithelial Neoplasia (AIN) / High-Grade Squamous Intraepithelial Lesions / Human Immunodeficiency Virus (HIV) Infections1
3Active Not RecruitingTreatmentNodular Basal Cell Carcinoma1
3Active Not RecruitingTreatmentPaget Disease, Extramammary1
3CompletedNot AvailableActinic Keratosis (AK)2
3CompletedNot AvailableKeratosis1
3CompletedDiagnosticActinic Keratosis (AK)1
3CompletedPreventionInfluenza Viral Infections1
3CompletedTreatmentActinic Keratosis (AK)7
3CompletedTreatmentBasal Cell Carcinoma (BCC)3
3CompletedTreatmentLeishmaniasis, Cutaneous1
3CompletedTreatmentNon-Melanomatous Skin Cancer1
3CompletedTreatmentScleroderma, Localized1
3CompletedTreatmentSuperficial Basal Cell Carcinoma1
3CompletedTreatmentVenereal Warts2
3Not Yet RecruitingTreatmentAnogenital Human Papillomavirus Infection / Condyloma Anal1
3Not Yet RecruitingTreatmentGenital Wart Virus Infection1
3RecruitingPreventionAnal Carcinoma / High-Grade Squamous Intraepithelial Lesions / Human Immunodeficiency Virus (HIV) Infections / Human Papilloma Virus Infection1
3RecruitingPreventionFlu caused by Influenza1
3RecruitingTreatmentCervical Intraepithelial Neoplasia (CIN)1
3RecruitingTreatmentHutchinson's Melanotic Freckle1
3RecruitingTreatmentLentigo Maligna Melanoma (Head or Neck)1
3RecruitingTreatmentVulvar Intraepithelial Neoplasia1
3TerminatedTreatmentCervical Intraepithelial Neoplasia (CIN)2
4Active Not RecruitingTreatmentActinic Keratosis (AK)1
4CompletedNot AvailableAlopecia Areata (AA)1
4CompletedTreatmentActinic Cheilitis1
4CompletedTreatmentActinic Keratosis (AK)4
4CompletedTreatmentActinic Keratosis (AK) / Keratosis1
4CompletedTreatmentAlopecia Areata (AA)1
4CompletedTreatmentBasal Cell Carcinoma (BCC)3
4CompletedTreatmentHutchinson's Melanotic Freckle1
4CompletedTreatmentVenereal Warts1
4TerminatedTreatmentActinic Keratosis (AK)2
4TerminatedTreatmentPlantar Warts1
4Unknown StatusNot AvailableActinic Keratosis (AK)1
4Unknown StatusTreatmentActinic Keratosis (AK)1
4Unknown StatusTreatmentBasal Cell Carcinoma (BCC)1
4WithdrawnTreatmentAnal Intraepithelial Neoplasia (AIN) / Human Immunodeficiency Virus (HIV) / Human Papilloma Virus (HPV)1
Not AvailableActive Not RecruitingTreatmentCervical Intraepithelial Neoplasia (CIN)1
Not AvailableCompletedNot AvailableActinic Keratosis (AK)1
Not AvailableCompletedPreventionIllness, Chronic1
Not AvailableCompletedTreatmentActinic Keratosis (AK)1
Not AvailableCompletedTreatmentHutchinson's Melanotic Freckle / Malignancies1
Not AvailableCompletedTreatmentPort Wine Stains1
Not AvailableCompletedTreatmentSolar Elastosis1
Not AvailableCompletedTreatmentVulvar Cancers1
Not AvailableNot Yet RecruitingBasic ScienceItching1
Not AvailableNot Yet RecruitingTreatmentMycosis Fungoides (MF)1
Not AvailableRecruitingBasic ScienceNormal Skin / Photoaged Skin1
Not AvailableRecruitingTreatmentCervical Intraepithelial Neoplasia 31
Not AvailableRecruitingTreatmentEpendymomas1
Not AvailableTerminatedNot AvailablePsoriasis1
Not AvailableUnknown StatusTreatmentBasal Cell Carcinoma (BCC)1
Not AvailableWithdrawnTreatmentActinic Keratosis (AK)1


  • Graceway pharmaceuticals llc
  • Nycomed us inc
  • Graceway Pharmaceuticals, LLC
  • 3M Health Care
  • Dispensing Solutions
  • E. Fougera and Co.
  • Graceway Pharmaceuticals
Dosage forms
CreamTopical50 mg/1000mg
CreamTopical12.5 mg/0.25g
CreamTopical37.5 mg/1g
CreamTopical50 mg/1g
CreamTopical2.5 mg/100mg
CreamTopical2.5 mg/1g
CreamTopical2.5 %
CreamTopical3.75 mg/100mg
CreamTopical3.75 %
Unit descriptionCostUnit
Aldara 5% Cream Pack46.99USD pack
Imiquimod 5% Cream Packet42.89USD packet
Imiquimod 5% cream33.17USD each
Aldara 5% cream26.04USD each
Zyclara 3.75% cream24.43USD each
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patent NumberPediatric ExtensionApprovedExpires (estimated)
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more


Experimental Properties
melting point (°C)292-294 °CNot Available
water solubilityPoorly solubleNot Available
logP2.7Not Available
Predicted Properties
Water Solubility0.247 mg/mLALOGPS
pKa (Strongest Basic)5.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area56.73 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity72.54 m3·mol-1ChemAxon
Polarizability26.67 Å3ChemAxon
Number of Rings3ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Human Intestinal Absorption+0.9967
Blood Brain Barrier+0.955
Caco-2 permeable+0.5995
P-glycoprotein substrateNon-substrate0.5137
P-glycoprotein inhibitor INon-inhibitor0.8797
P-glycoprotein inhibitor IIInhibitor0.6949
Renal organic cation transporterNon-inhibitor0.5928
CYP450 2C9 substrateNon-substrate0.8625
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.51
CYP450 1A2 substrateInhibitor0.8751
CYP450 2C9 inhibitorNon-inhibitor0.8182
CYP450 2D6 inhibitorInhibitor0.7628
CYP450 2C19 inhibitorNon-inhibitor0.634
CYP450 3A4 inhibitorNon-inhibitor0.5131
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6829
Ames testAMES toxic0.8884
BiodegradationNot ready biodegradable0.9916
Rat acute toxicity2.5683 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9546
hERG inhibition (predictor II)Inhibitor0.5422
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)


Mass Spec (NIST)
Not Available
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000f-2970000000-08cb009f804dd3b43f69
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-2910000000-58faefee0903c8967370


This compound belongs to the class of organic compounds known as imidazoquinolines. These are aromatic heterocyclic compounds containing an imidazole ring fused to a quinoline ring system. In some configurations, the imidazole ring shares a nitrogen atom with the quinoline moiety.
Organic compounds
Super Class
Organoheterocyclic compounds
Quinolines and derivatives
Sub Class
Direct Parent
Alternative Parents
Aminoquinolines and derivatives / Imidazo-[4,5-c]pyridines / Aminopyridines and derivatives / N-substituted imidazoles / Imidolactams / Benzenoids / Heteroaromatic compounds / Azacyclic compounds / Primary amines / Organopnictogen compounds
show 1 more
Imidazoquinoline / Aminoquinoline / Imidazopyridine / Imidazo-[4,5-c]pyridine / Aminopyridine / N-substituted imidazole / Pyridine / Imidolactam / Benzenoid / Azole
show 10 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
imidazoquinoline (CHEBI:36704)


1. Toll-like receptor 7
Pharmacological action
General Function
Transmembrane signaling receptor activity
Specific Function
Key component of innate and adaptive immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR7 i...
Gene Name
Uniprot ID
Uniprot Name
Toll-like receptor 7
Molecular Weight
120920.8 Da
  1. Gibson SJ, Lindh JM, Riter TR, Gleason RM, Rogers LM, Fuller AE, Oesterich JL, Gorden KB, Qiu X, McKane SW, Noelle RJ, Miller RL, Kedl RM, Fitzgerald-Bocarsly P, Tomai MA, Vasilakos JP: Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol. 2002 Jul-Aug;218(1-2):74-86. [PubMed:12470615]
  2. Akira S, Hemmi H: Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett. 2003 Jan 22;85(2):85-95. [PubMed:12527213]
  3. Dummer R, Urosevic M, Kempf W, Hoek K, Hafner J, Burg G: Imiquimod in basal cell carcinoma: how does it work? Br J Dermatol. 2003 Nov;149 Suppl 66:57-8. [PubMed:14616353]
  4. Otero M, Calarota SA, Felber B, Laddy D, Pavlakis G, Boyer JD, Weiner DB: Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model. Vaccine. 2004 Apr 16;22(13-14):1782-90. [PubMed:15068862]
  5. Ambach A, Bonnekoh B, Nguyen M, Schon MP, Gollnick H: Imiquimod, a Toll-like receptor-7 agonist, induces perforin in cytotoxic T lymphocytes in vitro. Mol Immunol. 2004 Apr;40(18):1307-14. [PubMed:15072849]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Pharmacological action
General Function
Single-stranded rna binding
Specific Function
Key component of innate and adaptive immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. Acts v...
Gene Name
Uniprot ID
Uniprot Name
Toll-like receptor 8
Molecular Weight
119826.82 Da
  1. Dummer R, Urosevic M, Kempf W, Hoek K, Hafner J, Burg G: Imiquimod in basal cell carcinoma: how does it work? Br J Dermatol. 2003 Nov;149 Suppl 66:57-8. [PubMed:14616353]
  2. Zhu J, Lai K, Brownile R, Babiuk LA, Mutwiri GK: Porcine TLR8 and TLR7 are both activated by a selective TLR7 ligand, imiquimod. Mol Immunol. 2008 Jun;45(11):3238-43. doi: 10.1016/j.molimm.2008.02.028. Epub 2008 Apr 24. [PubMed:18439678]
  3. Gorden KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, Qiu X, Tomai MA, Alkan SS, Vasilakos JP: Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol. 2005 Feb 1;174(3):1259-68. [PubMed:15661881]


Pharmacological action
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
Uniprot ID
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
  1. Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [PubMed:11996015]

Drug created on June 13, 2005 07:24 / Updated on December 08, 2019 20:10